Guidance on Meetings with Industry and Investigators on the Research and Development of Tobacco Products

ICR 202509-0910-001

OMB: 0910-0731

Federal Form Document

Forms and Documents
Document
Name
Status
Supporting Statement A
2025-09-16
ICR Details
0910-0731 202509-0910-001
Received in OIRA 202410-0910-008
HHS/FDA CTP
Guidance on Meetings with Industry and Investigators on the Research and Development of Tobacco Products
Revision of a currently approved collection   No
Regular 09/19/2025
  Requested Previously Approved
36 Months From Approved 09/30/2025
20 65
600 1,820
0 0

This ICR is for a guidance intended to assist tobacco manufacturers, importers, researchers, and investigators, and their representatives who seek meetings with staff of FDA’s Center for Tobacco Products (CTP). This guidance does not pertain to other types of meetings or meeting requests with CTP staff. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act) offers several pathways to obtain an order from FDA to authorize the marketing of a new tobacco product before it may be introduced or delivered into interstate commerce. To provide assistance with these pathways to market products, FDA will meet with tobacco product manufacturers, importers, researchers, and investigators (or their representatives) where appropriate. This guidance is intended to assist persons who seek guidance relating to their research to inform the regulation of tobacco products or to support the development or marketing of tobacco products. This guidance describes two collections of information: (1) The submission of a meeting request containing certain information and (2) the submission of a meeting information package in advance of the meeting. The purpose of the meeting information package is to provide Agency staff the opportunity to adequately prepare for the meeting, including the review of relevant data concerning the product. In the Agency’s experience, reviewing such information is critical to achieving a productive meeting. For information that was previously submitted in a meeting request, the information package should provide updated information that reflects the most current and accurate information available.

PL: Pub.L. 111 - 111 31 Name of Law: Family Smoking Prevention and Tobacco Control Act
  
None

Not associated with rulemaking

  90 FR 27636 06/27/2025
90 FR 45227 09/19/2025
No

1
IC Title Form No. Form Name
Guidance on Meetings with Industry and Investigators on the Research and Development of Tobacco Products

  Total Request Previously Approved Change Due to New Statute Change Due to Agency Discretion Change Due to Adjustment in Estimate Change Due to Potential Violation of the PRA
Annual Number of Responses 20 65 0 0 -45 0
Annual Time Burden (Hours) 600 1,820 0 0 -1,220 0
Annual Cost Burden (Dollars) 0 0 0 0 0 0
No
No
Based on the combined impacts of program changes and adjustments describes above, FDA’s estimated burden for the entire information collection reflects an overall annual decrease of 1,220 hours and 90 respondents (45 fewer respondents submitting meeting requests, and 45 fewer respondents submitting metting information packages). The total burden hours for the collection have been reduced from 1,820 hours to 600 total hours. FDA’s estimated cost burden to the respondents has increased from $53,437.20 to $92,274 due to a re-assessment of staff occupational employment categories needed to create and review meeting requests and packages.

$265,276
No
    Yes
    No
No
No
No
No
Amber Sanford 301 796-8867 amber.sanford@fda.hhs.gov

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
09/19/2025


© 2025 OMB.report | Privacy Policy